Curevac gets $300 million grant to hurry up Covid-19 vaccine

accreditation
0:00
play article
Subscribers can listen to this article
(File, Getty)
(File, Getty)
  • Curevac, a German boitech firm has won almost $300 million in government funding to hurry up its prototype vaccine for Covid-19.
  • The funding will be recieved in two batches - the first this year and the second in 2021.
  • Curevac aimed to produce 100 million doses of its vaccine by the end of this year.


German biotech firm Curevac said on Friday it had won nearly $300 million in government funding to speed up work on its prototype Covid-19 vaccine and build capacity to produce it at scale.

The Tuebingen-based startup, valued at $10 billion after floating last month on Nasdaq, is one of a number of firms designing vaccines based on molecules carrying a genetic code called messenger RNA (mRNA).

CEO Franz-Werner Haas said the money "can substantially support our efforts to produce and develop a safe and effective vaccine in high volume as quickly as possible."

Curevac said it had been awarded 252 million euros ($298 million) to support its vaccine candidate, after applying under a scheme announced in July by Science Minister Anja Karliczek.

It expects to receive the funding in two tranches - a first of up to 103 million euros this year and a second of up to 149 million euros in 2021 - subject to agreed targets.

Data carrier

Curevac's technology uses mRNA as a data carrier to instruct the human body to produce proteins that can fight against diseases. Uses include prophylactic vaccines, cancer therapies, antibody therapies and rare diseases.

Curevac is likely to be beaten to market by US rival Moderna and Germany's Biontech, billionaire backer Dietmar Hopp said earlier.

"We can't win this race," Hopp told the Handelsblatt business daily. "But we want to win the race to produce the best vaccine and here we have good chances."

Hopp, one of the founders of software company SAP, said Curevac aimed to produce 100 million doses of its vaccine by the end of this year.

Curevac may also expand its cooperation with Grohmann, a subsidiary of Elon Musk's electric car maker Tesla, in developing so-called RNA printers that would make it possible to decentralise production, Hopp also said.

Musk was in Germany this week and visited Curevac, sparking press speculation that he may invest in the company. Hopp earlier dismissed the reports as "pure fantasy".

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
Should Covid-19 vaccinations be mandatory for employees in workplaces?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes, it is the responsible thing to do
47% - 4385 votes
No, vaccination should be an individual choice
43% - 4033 votes
No, but those who are unvaccinated should have to work from home
11% - 996 votes
Vote
Rand - Dollar
14.61
-0.2%
Rand - Pound
20.32
-0.1%
Rand - Euro
17.34
-0.0%
Rand - Aus dollar
10.72
+0.1%
Rand - Yen
0.13
-0.1%
Gold
1,814.19
0.0%
Silver
25.49
0.0%
Palladium
2,662.50
0.0%
Platinum
1,051.86
0.0%
Brent Crude
75.41
+0.4%
Top 40
62,852
-0.9%
All Share
68,971
-0.9%
Resource 10
70,683
-2.0%
Industrial 25
88,051
-0.4%
Financial 15
12,906
+0.6%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE